Biostime brushes off melamine scandal with European production lines to price mid range
Biostime International Holdings, the pediatric nutrition and baby care product producer, braved a volatile Hong Kong market this week to successfully price a HK$1.7bn ($212m) IPO in the middle of its price range.
The company fought off association with poor performing IPOs from the same sector, which continues to suffer from Chinas melamine scandal. Biostime instead emphasised its European production lines, its well known brand in China and its growth potential in the sector.
"The company really focused on its brand
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: firstname.lastname@example.org
To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: email@example.com or find out more online here.